Company: TCRG
Filing Date: 2025-03-21
Form Type: 10-K
Source: 0001185185-25-000206
Chunk: 9

Company: Cannaisseur Group Inc.
Filing Date: 2025-03-21
Form: 10-K
Item: Item 1
Chunk 9
---
 supply may be affected, and it may incur increased labor costs. In addition, the Company
may experience difficulties with certain suppliers or with vendors in its supply chains, and its business could be affected if the Company
becomes unable to procure essential equipment, supplies or services in adequate quantities and at acceptable prices. Further, an infectious
outbreak may cause disruption to the U.S. economy, or the local economies of the markets in which the Company operates, increase costs
associated with its business, affect job growth and consumer confidence, or cause economic changes that the Company cannot anticipate.
Overall, the potential impact of a pandemic, epidemic or outbreak of an infectious disease with respect to the Company’s markets
or its facilities is difficult to predict and could adversely impact the Company’s business. Given that the type, degree, and length
of such restrictions are not known at this time, the Company cannot predict the overall impact of such restrictions on it, its customers,
its subcontractors, and others with whom the Company works or the overall economic environment.

Our
industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal
Trade Commission (FTC)

The
FDA under the Federal Food, Drug, and Cosmetic Act regulates the formulation, manufacturing, packaging, labeling, and distribution of
food, dietary supplements, drugs, cosmetic, medical devices, biologics, and tobacco products. Our hemp-derived CBD products are not intended
to be drugs. Accordingly, we have not been required to obtain FDA approval for our existing hemp-derived CBD products. Moreover, the
regulatory status of hemp-derived CBD products is in a state of flux as FDA attempts to determine the appropriate manner in which to
regulate these products. Thus, the regulatory approach is still evolving, and we may be required to seek FDA’s approval to market
food and dietary supplements containing hemp-derived CBD. It is also possible that the FDA may simply issue a regulation setting forth
the conditions in which such products may be marketed, or it may simply prohibit these products. However, because FDA’s regulatory
process is in its infancy, we cannot predict the likely outcome. (See preceding Section, “Government Regulation”.) In addition,
the FTC under the Federal Trade Commission Act (“FTC Act”) requires that product advertising be truthful, substantiated,
and non-misleading. We believe that our advertising meets these requirements. However, the FTC may bring a challenge at any time to evaluate
our compliance with the FTC Act.

Increases